01.12.2017 | Research article | Ausgabe 1/2017 Open Access

UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression
- Zeitschrift:
- BMC Cancer > Ausgabe 1/2017
Background
Methods
Study design
Immunohistochemistry of tissue microarrays
Image analysis
Statistical analysis
Results
All patients
(
N = 190)
|
|
---|---|
Age, M (Q1-Q3)
|
63 (58-67)
|
Race, n(%)
|
|
Non-black
|
99 (52)
|
Black
|
91 (48)
|
Year of Surgery, M (Q1-Q3)
|
2001 (1997-2002)
|
PSA (ng/mL), M (Q1-Q3)
|
7.4 (5.1-11.1)
|
Pathological Gleason, n(%):
|
|
2 – 6
|
39 (20)
|
(3 + 4)
|
100 (53)
|
(4 + 3) – 10
|
51 (27)
|
Positive Margins, n(%)
|
115 (61)
|
Seminal Vesicle Invasion, n(%)
|
28 (15)
|
Extracapsular Extension, n(%)
|
51 (27)
|
Positive Lymph Nodes, n(%)
|
1 (<1)
|
Average % Cells Positive for UGT2B15, M(Q1-Q3)
|
39 (24-61)
|
Average % Cells Positive for UGT2B17, M(Q1-Q3)
|
74 (59-86)
|
Average % Cells Positive for UGT2B28, M(Q1-Q3)
|
77 (60-91)
|
UGT2B15 H-score, M(Q1-Q3)
|
40 (24-63)
|
UGT2B17 H-score, M(Q1-Q3)
|
76 (59-92)
|
UGT2B28 H-score, M(Q1-Q3)
|
86 (64-107)
|
PSA Follow-up (months), M(Q1-Q3)
|
118 (85-144)
|
UGT2B15
|
UGT2B17
|
UGT2B28
|
||||
---|---|---|---|---|---|---|
Predictor
|
HR (95% CI)
|
p-value
|
HR (95% CI)
|
p-value
|
HR (95% CI)
|
p-value
|
% Positive
|
||||||
Crude
|
1.98 (0.90-1.07)
|
0.70
|
1.11 (0.98-1.25)
|
0.09
|
1.02 (0.92-1.13)
|
0.70
|
Adjusted
a
|
1.02 (0.93-1.12)
|
0.72
|
1.10 (0.98-1.25)
|
0.11
|
1.08 (0.96-1.21)
|
0.21
|
H-score
|
||||||
Crude
|
0.99 (0.91-1.07)
|
0.80
|
1.05 (0.97-1.13)
|
0.21
|
1.00 (0.94-1.06)
|
0.89
|
Adjusted
a
|
1.03 (0.94-1.12)
|
0.57
|
1.03 (0.96-1.11)
|
0.42
|
1.04 (0.97-1.11)
|
0.26
|
Crude
|
Adjusted
a
|
|||
---|---|---|---|---|
UGT2B17 total positive
|
HR (95% CI)
|
p-value
|
HR (95% CI)
|
p-value
|
Group 1
|
Reference
|
-
|
Reference
|
-
|
Group 2
|
1.574 (1.018, 2.434)
|
0.041
|
1.502 (0.941, 2.398)
|
0.088
|
UGT2B17 H-score
|
||||
Group 1
|
Reference
|
-
|
Reference
|
-
|
Group 2
|
1.324 (0.859, 2.039)
|
0.203
|
1.259 (0.780, 1.983)
|
0.319
|
Pathological Gleason Score
|
||||
---|---|---|---|---|
2 – 6
|
3 + 4
|
(4 + 3) – 10
|
P-value
|
|
UGT2B15
|
0.55*
|
|||
Median
|
42.8
|
39.0
|
31.3
|
|
Q1-Q3
|
28.8-61.9
|
21.5-65.9
|
24.5-50.5
|
|
< Median
|
16 (41%)
|
48 (48%)
|
31 (61%)
|
0.15**
|
≥ Median
|
23 (59%)
|
52 (52%)
|
20 (39%)
|
|
UGT2B17
|
0.84*
|
|||
Median
|
72.4
|
78.5
|
78.2
|
|
Q1-Q3
|
59.8-88.1
|
58.6-94.9
|
68.2-84.6
|
|
< Median
|
22 (56%)
|
48 (48%)
|
25 (49%)
|
0.66**
|
≥ Median
|
17 (44%)
|
52 (52%)
|
26 (51%)
|
|
UGT2B28
|
0.89*
|
|||
Median
|
86.0
|
86.0
|
86.4
|
|
Q1-Q3
|
58.4-102.9
|
63.6-109.3
|
74.1-102.2
|
|
< Median
|
20 (51%)
|
50 (50%)
|
25 (49%)
|
0.98**
|
≥ Median
|
19 (49%)
|
50 (50%)
|
26 (51%)
|